Inhibiting interleukin-6 in rheumatoid arthritis

Current Rheumatology Reports

Volumn 10, Issue 5, 2008, Pages 413-417

  Choy, Ernest ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATLIZUMAB; INTERLEUKIN 6; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; ANTIRHEUMATIC AGENT; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ANEMIA; ARTHRITIS; BINDING AFFINITY; CELL MIGRATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENE FUNCTION; HELPER CELL; HUMAN; IMMUNE RESPONSE; JOINT DESTRUCTION; LEUKOCYTE; LIVER FUNCTION; MONOTHERAPY; NEUTROPENIA; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PANNUS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TH7 CELL; TREATMENT RESPONSE; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; METABOLISM; PHASE 3 CLINICAL TRIAL;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; INTERLEUKIN-6; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 55949136066     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-008-0066-x     Document Type: Review

References (36)

1. Young A, Koduri G, Batley M, et al.: Early Rheumatoid Arthritis Study (ERAS) Group: Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 2007, 46: 350-357.
2. Pincus T, Callahan LF: Remodeling the pyramid or remodeling the paradigms concerning rheumatoid arthritis-lessons from Hodgkin's disease and coronary artery disease. J Rheumatol 1990, 17: 1582-1585.
3. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines: Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002, 46: 328-346.
4. Kishimoto T: The biology of interleukin-6. Blood 1989, 74: 1-10.
5. Jones S, Richards PJ, Scheller J, Rose-John S: IL-6 transsignaling: The in vivo consequences. J Interferon Cytokine Res 2005, 25: 241-253.
6. Harrington L, Hatton RD, Mangan PR, et al.: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunol 2005, 6: 1123-1132.
7. Hirota K, Hashimoto M, Yoshitomi H, et al.: T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med 2007, 204: 41-47.
8. Bettelli E, Carrier Y, Gao W, et al.: Reciprocal development pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441: 235-238.
9. Madhok R, Crilly A, Watson J, Capell HA: Serum interleukin 6 levels in rheumatoid arthritis: Correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993, 52: 232-234.
10. Uson J, Balsa A, Pascual-Salcedo D, et al.: Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J Rheumatol 1997, 24: 2069-2075.
11. Kotake S, Sato K, Kim KJ, et al.: Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996, 11: 88-95.
12. Brozik M, Rosztoczy I, Meretey K, et al.: Interleukin 6 levels in synovial fluids of patients with different arthritides: Correlation with local IgM rheumatoid factor and systemic acute phase protein production. J Rheumatol 1992, 19: 63-68.
13. Romano M, Sironi M, Toniatti C, et al.: Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997, 6: 315-325.
14. Lally F, Smith E, Filer A, et al.: A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthritis Rheum 2005, 52: 3460-3469.
15. Nakahara H, Song J, Sugimoto M, et al.: Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003, 48: 1521-1529.
16. Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegrin/ RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292: 490-495.
17. Devlin RD, Reddy SV, Savino R, et al.: IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures. J Bone Miner Res 1998, 13: 393-399.
18. Gorny G, Shaw A, Oursler MJ: IL-6, LIF, and TNF-alpha regulation of GM-CSF inhibition of osteoclastogenesis in vitro. Exp Cell Res 2004, 294: 149-158.
19. Guerne PA, Zuraw BL, Vaughan JH, et al.: Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J Clin Invest 1989, 83: 585-592.
20. Dasgupta B, Corkill M, Kirkham B, et al.: Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 1992, 19: 22-25.
21. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340: 448-454.
22. Han C, Rahman MU, Doyle MK, et al.: Association of anemia and physical disability among patients with rheumatoid arthritis. J Rheumatol 2007, 34: 2177-2182.
23. Jongen-Lavrencic M, Peeters HR, Rozemuller H, et al.: IL-6-induced anaemia in rats: Possible pathogenetic implications for anemia observed in chronic inflammations. Clin Exp Immunol 1996, 103: 328-334.
24. Voulgari PV, Kolios G, Papadopoulos GK, et al.: Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin Immunol 1999, 92: 153-160.
25. Nemeth E, Tuttle MS, Powelson J, et al.: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306: 2090-2093.
26. Lipsky PE: Interleukin-6 and rheumatic diseases. Arthritis Res Ther 2006, 8(Suppl 2): S4.
27. De Benedetti F, Rucci N, Del Fattore A, et al.: Impaired skeletal development in interleukin-6-transgenic mice: A model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 2006, 54: 3551-3563.
28. Choy EH, Isenberg DA, Garrood T, et al.: Therapeutic benefit of blocking interleukin-6 activity with an antiinterleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002, 46: 3143-3150.
29. Nishimoto N, Yoshizaki K, Miyasaka N, et al.: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebocontrolled trial. Arthritis Rheum 2004, 50: 1761-1769.
30. Maini RN, Taylor PC, Szechinski J, et al.: CHARISMA Study Group: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006, 54: 2817-2829.
31. Nishimoto N, Hashimoto J, Miyasaka N, et al.: Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007, 66: 1162-1167.
32. Smolen JS, Beaulieu A, Rubbert-Roth A, et al.: OPTION Investigators: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 2008, 371: 987-997.
33. Smolen J, Rovensky J, Ramos-Remus C, et al.: Targeting the IL-6 receptor with the monoclonal antibody tocilizumab significantly improves quality of life with rheumatoid arthritis [presentation 292]. Presented at the American College of Rheumatology/Association of Rheumatology Professionals 2007 Scientific Meeting. Boston, MA; November 6-11, 2008.
34. Frey N, Grange S, Woodworth T, et al.: Relationship between serum concentrations of the interleukin-6 receptor inhibitor tocilizumab and C-reactive protein reduction in RA patients: 6 months' data from a phase 3 study [presentation 259]. Presented at the American College of Rheumatology/Association of Rheumatology Professionals 2007 Scientific Meeting. Boston, MA; November 6-11, 2008.
35. Genovese M, McKay J, Nasonov E, et al.: IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: The TOWARD study [presentation L15]. Presented at the American College of Rheumatology/Association of Rheumatology Professionals 2007 Scientific Meeting. Boston, MA; November 6-11, 2008.
36. Gomez-Reino JJ, Fairfax MJ, Pavelka K, et al.: Targeted inhibition of IL-6 signaling with tocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs [presentation L6]. Presented at the American College of Rheumatology/Association of Rheumatology Professionals 2007 Scientific Meeting. Boston, MA; November 6-11, 2008.